Resource Summary Report

Generated by dkNET on Sep 13, 2026

A-673

RRID:CVCL_0080
Type: Cell Line

Proper Citation

RRID:CVCL_0080

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0080

Proper Citation: RRID:CVCL_0080

Description: Cell line A-673 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ewing sarcoma

Defining Citation: PMID:212188, PMID:327080, PMID:375235, PMID:3335022, PMID:4357758, PMID:6173755, PMID:6256643, PMID:6825208, PMID:6954533, PMID:8275086, PMID:8378080, PMID:10379870, PMID:11423975, PMID:12068308, PMID:12606131, PMID:14697648, PMID:16888811, PMID:17431109, PMID:19787792, PMID:20164919, PMID:20215515, PMID:21822310, PMID:22142829, PMID:22282976, PMID:22460905, PMID:23882450, PMID:24312454, PMID:24758355, PMID:25010205, PMID:25223734, PMID:25485619, PMID:25877200, PMID:25984343, PMID:26351324, PMID:26428435, PMID:26589293, PMID:26979953, PMID:27397505, PMID:28196595, PMID:30879952, PMID:30894373, PMID:31068700, PMID:31978347, PMID:34413129, PMID:35839778, PMID:36476851

Comments: Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: Ewing Sarcoma Cell Line Atlas (ESCLA)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misclassified. Originally thought to be a rhabdomyosarcoma cell line but shown to be from an Ewing sarcoma (PubMed=10379870; PubMed=12606131; PubMed=14697648)..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: A-673

Synonyms: A673, RMS 1598, RMS1598

Cross References: BTO:BTO_0003768, CLO:CLO_0001605, CLO:CLO_0001606, EFO:EFO_0002106, CLDB:cl166, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1598, ATCC:CRL-7910, BioGRID_ORCS_Cell_line:160, BioSample:SAMN03473282, BioSample:SAMN10987881, cancercelllines:CVCL_0080, CCRID:3101HUMTCHu223, Cell_Model_Passport:SIDM00848, ChEMBL-Cells:CHEMBL3307384, ChEMBL-Targets:CHEMBL614517, CLS:300454, Cosmic:684052, Cosmic:1091064, Cosmic:1097757, Cosmic:1388901, Cosmic:1718108, Cosmic:1995338, Cosmic:2228213, Cosmic:2250469, Cosmic:2294580, Cosmic-CLP:684052, DepMap:ACH-000052, ECACC:85111504, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS304EKV, ENCODE:ENCBS385OLC, ENCODE:ENCBS615MBV, ENCODE:ENCBS790NPQ, GDSC:684052, GEO:GSM510002, GEO:GSM827304, GEO:GSM886859, GEO:GSM887924, GEO:GSM1669590, GEO:GSM1676306, GEO:GSM1701623, GEO:GSM1899422, GEO:GSM5359628, GEO:GSM5359629, GEO:GSM5359630, GEO:GSM5359631, GEO:GSM5359632, GEO:GSM5359633, GEO:GSM5362876, GEO:GSM5362877, GEO:GSM5362878, GEO:GSM5362879, GEO:GSM5362880, GEO:GSM5362881, GEO:GSM5363936, GEO:GSM5363937, GEO:GSM5363938, GEO:GSM5363939, GEO:GSM5363940, IARC_TP53:705, IARC_TP53:21168, IGRhCellID:A673, KCLB:21598, LiGeA:CCLE_182, LINCS_LDP:LCL-1410, Lonza:1455, PharmacoDB:A673_49_2019, PRIDE:PXD030304, Progenetix:CVCL_0080, PubChem_Cell_line:CVCL_0080, Wikidata:Q54606055

ID: CVCL_0080

Record Creation Time: 20220427T215104+0000

Record Last Update: 20260913T011850+0000

Ratings and Alerts

No rating or validation information has been found for A-673.

Warning: Problematic cell line: Misclassified. Originally thought to be a rhabdomyosarcoma cell line but shown to be from an Ewing sarcoma (PubMed=10379870; PubMed=12606131; PubMed=14697648).
Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: Ewing Sarcoma Cell Line Atlas (ESCLA)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misclassified. Originally thought to be a rhabdomyosarcoma cell line but shown to be from an Ewing sarcoma (PubMed=10379870; PubMed=12606131; PubMed=14697648).. Warning: Discontinued: ATCC; CRL-7910
Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: Ewing Sarcoma Cell Line Atlas (ESCLA)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).,

Problematic cell line: Misclassified. Originally thought to be a rhabdomyosarcoma cell line but shown to be from an Ewing sarcoma (PubMed=10379870; PubMed=12606131; PubMed=14697648)..

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 276 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Ji YR, et al. (2026) Detection of Extracellular Vesicles with Colocalized Surface Markers via a Capture-Release-Capture Strategy for Treatment Monitoring in Ewing Sarcoma. Advanced healthcare materials, 15(18), e05917.

Gracilla DE, et al. (2026) FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy. Cancer research, 86(11), 2660.

Downing NF, et al. (2026) PRC2/FOXO1-Mediated Repression Determines Interchangeability of ETS Oncogenes in Prostate Cancer and Ewing Sarcoma. Molecular cancer research : MCR, 24(1), 48.

Milovanovi? D, et al. (2026) Tissue-specific restriction of transposon-derived regulatory elements safeguards cell-type identity. Cell reports, 45(1), 116817.

Suresh V, et al. (2026) Modelling EWS::FLI1 protein fluctuations reveal determinants of tumor plasticity in Ewing sarcoma. EMBO molecular medicine, 18(2), 646.

Dreher RD, et al. (2026) LSD1 Performs Demethylase-Independent and Context-Specific Roles in Ewing Sarcoma. Cancer research communications, 6(3), 585.

Burke CM, et al. (2026) Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. Molecular cancer therapeutics, 25(1), 156.

Porazzi P, et al. (2025) EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer cell, 43(3), 537.

Ziener J, et al. (2025) Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing's sarcoma cells. BMC cancer, 25(1), 277.

Rask GC, et al. (2025) Seclidemstat (SP-2577) Induces Transcriptomic Reprogramming and Cytotoxicity in Multiple Fusion-Positive Sarcomas. Cancer research communications, 5(9), 1584.

Dreher RD, et al. (2025) LSD1 Performs Demethylase-Independent and Context-Specific Roles in Ewing Sarcoma. bioRxiv : the preprint server for biology.

Figuerola-Bou E, et al. (2025) KDM6 Demethylases Contribute to EWSR1::FLI1-Driven Oncogenic Reprogramming in Ewing Sarcoma. Cancer research, 85(22), 4485.

Noorizadeh R, et al. (2025) YAP1 is a key regulator of EWS::FLI1-dependent malignant transformation upon IGF-1-mediated reprogramming of bone mesenchymal stem cells. Cell reports, 44(3), 115381.

Chicón-Bosch M, et al. (2025) Multi-omics profiling reveals key factors involved in Ewing sarcoma metastasis. Molecular oncology, 19(4), 1002.

Berger HR, et al. (2025) Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas. Cancer immunology research, 13(10), 1591.

Ceranski AK, et al. (2025) Refined culture conditions with increased physiological relevance uncover oncogene-dependent metabolic signatures in Ewing sarcoma spheroids. Cell reports methods, 5(2), 100966.

Manara MC, et al. (2024) Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages. Cancer immunology research, 12(2), 247.

Graca Marques J, et al. (2024) The Chromatin Remodeler CHD4 Sustains Ewing Sarcoma Cell Survival by Controlling Global Chromatin Architecture. Cancer research, 84(2), 241.

Pezzella M, et al. (2024) Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells. Journal of hematology & oncology, 17(1), 127.

Suvarna K, et al. (2024) Ceramide-induced cleavage of GPR64 intracellular domain drives Ewing sarcoma. Cell reports, 43(8), 114497.